PubMed Health⌕ Search

Biomedical subjects

L W Miller

Publications and source records attributed to L W Miller.

At least 73 records · Page 4Linked to original sources
PubMed1989

Use of the Pierce-Donachy ventricular assist device in patients with cardiogenic shock after cardiac operations.

In spite of recent improvements in cardiac surgery, a small percentage of patients have severe postcardiotomy ventricular failure refractory to drugs and the intraaortic balloon. In our experience, the Pierce-Donachy external pneumatic ventricular assist device has proved to be one of the most effective devices for these patients. Since 1981, 30 patients aged 15 to 71 years (mean age, 52 years) with profound cardiogenic shock refractory to conventional therapy after cardiotomy were supported with the Pierce-Donachy ventricular assist device. Fourteen required left ventricular support, 7 needed right ventricular support with an intraaortic balloon, and 9 had biventricular assistance. Duration of support ranged from three hours to 22 days (mean length, 3.6 days). Seven of the first 11 patients seen died in the operating room of bleeding, biventricular failure, or both. However, 16 patients (53%) had improved cardiac function, 15 (50%) were weaned, and 11 (37%) were discharged. Of the last 19 patients in the series, 47% survived. Factors affecting survival were myocardial infarction (75%) and renal failure (90%). Common complications were bleeding (73%) and biventricular failure (83%).

Adolescent↗
PubMed1989

Axillary artery insertion of an intraaortic balloon pump.

We describe a technique for insertion of an intraaortic balloon pump through the axillary artery. This approach is useful in patients requiring intraaortic balloon pump support before cardiac transplantation in that it dramatically increases patient mobility while awaiting a donor heart.

Axillary Artery↗
PubMed1989

T cells in ventricular assist device patients.

Levels of T lymphocytes were measured in 20 consecutive patients, 18 men and two women, supported with ventricular assist devices or an artificial heart. Indications for support were bridge to transplantation (n = 10), postcardiotomy cardiogenic shock (n = 8), and acute myocardial infarction shock (n = 2). Control levels were from healthy volunteers not undergoing cardiac operation. Preoperatively, numbers of total lymphocytes and subclasses CD3, CD4, and CD8, as well as the interleukin-2 receptors (IL2R), were the same as controls (cells/microliters): lymphocytes, 1,940; CD3, 1,413 +/- 410; CD4, 894 +/- 318; CD8, 490 +/- 185; IL2R, 96. From implant to postoperative day 5, levels were below control values (p less than 0.001), reaching a nadir on postoperative day 2 (lymphocytes, 896 +/- 599; CD3, 489 +/- 267; CD4, 309 +/- 207; CD8, 183 +/- 107; IL2R, 43 +/- 47). Data from 10 patients (group 1) who survived (four weaned from cardiopulmonary bypass, six transplanted) were compared with those from 10 patients (group 2) who died of multiorgan failure, sepsis, or both. From preimplant through postoperative day 6, levels did not differ between groups. However, from postoperative day 7 to the last day of ventricular support (group 1, 24-90 days; group 2, 7-29 days), group 1 levels (lymphocytes, 2,364 +/- 618; CD3, 1,825 +/- 553; CD4, 1,013 +/- 187; CD8, 796 +/- 402) were significantly above (p less than 0.01) group 2 levels (lymphocytes, 1,290 +/- 463; CD3, 746 +/- 295; CD4, 534 +/- 253; CD8, 221 +/- 106). These data indicate that lymphocytes and particularly T cells 1) decrease after ventricular assist device insertion, reaching a nadir at postoperative day 2, 2) return to control values after patients whose clinical status improves, and 3) remain low in severely ill patients. T-cell depression in ventricular assist device patients is related to the severity of the patient's condition rather than the presence of the device.

Adult↗
PubMed1988

Bridging to cardiac transplantation with pulsatile ventricular assist devices.

As cardiac transplantation becomes more commonplace in the treatment of end-stage heart failure and as suitable donors become less available, an increasing number of patients will require mechanical circulatory assistance to bridge to transplantation. Since 1982, refractory hemodynamic instability requiring placement of pulsatile ventricular assist devices (VADs) has developed in 11 candidates for transplantation aged 24 to 54 years (mean, 39.6 years). A pneumatic Pierce-Donachy pump was used in 9 patients and an electrical Novacor pump in 2. The cause of the cardiomyopathy was ischemic in 6, postpartum in 2, idiopathic in 2, and doxorubicin hydrochloride toxicity in 1. Seven patients required left ventricular support (LVAD); 4 required biventricular mechanical support (BVAD). Duration of support ranged from 8 hours to 91 days with flows ranging from 4.1 to 8.5 L/min (mean, 5.5 L/min). Although hemodynamic stability was achieved in all 11 patients, contraindications to transplantation developed in 5 patients during VAD support (renal failure in 4, sepsis in 3, disseminated intravascular coagulopathy in 1). The remaining 6 patients (4 with an LVAD, 2 with a BVAD) remained good candidates for transplantation despite major complications in 5 (mediastinal bleeding in 3, driveline infection in 3, development of preformed antibodies in 2, small embolic stroke caused by device malfunction in 1). The 3 patients who were supported the longest (24, 75, and 91 days) were ambulatory while awaiting a donor heart. All 6 patients underwent successful transplantation after 8 hours to 91 days (mean, 24 days) of support. Other than one sternal wound infection, there were no major complications after transplantation.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute Kidney Injury↗
PubMed1988

Role of interleukin 2 receptors in immunologic monitoring following cardiac transplantation.

Two-color flow cytometry was used to measure lymphocyte activation antigens, IL-2 receptor (IL-2R), and HLA-DR, on T helper/inducer and cytotoxic/suppressor subsets in the peripheral blood of cardiac transplant patients. Data including 213 cardiac biopsies to determine rejection were obtained on 24 consecutive recipients receiving cyclosporine and prednisone, who survived greater than 5 weeks. The results showed a correlation between the presence of CD4(T4)-IL-2R and rejections or infection occurring within the first 5 weeks posttransplantation. Sensitivity was 79% (73% for rejection only) specificity 97%, P less than .001 by Fisher's exact test. The number of T4-IL-2R cells peaked at 213 cells/microliter with a mean lead time of approximately 3 days prior to positive biopsy (n = 8). After 5 weeks posttransplantation, the sensitivity decreased to 35% (25% rejection only). This decrease may be due to the lack of samples immediately prior to biopsy in patients after 5 weeks posttransplantation. CD8(T8)-IL-2R, T8-DR, T4-DR levels did not correlate with rejections. The results suggest that T4-IL-2R cells that escape cyclosporine inhibition are highly correlated with rejection and enumeration may contribute to increased utility of immune monitoring in these patients.

Adult↗
PubMed1988

Echocardiography-guided endomyocardial biopsy. A 5-year experience.

The number of cardiac transplant procedures performed each year continues to increase and may exceed 1,600 procedures in 1987. In these patients, the diagnosis of rejection is obtained from serial endomyocardial biopsy. The absence of clinical symptoms associated with allograft rejection with cyclosporine therapy has necessitated a predetermined routine biopsy frequency that averages 10-15 biopsies per patient in the first posttransplant year. Traditionally, fluoroscopy has been used to guide the biopsy, but this technique has a number of negative features, including cumulative radiation exposure in the physician and the patient, limited portability, and the limited area of access (intraventricular septum) for biopsy. In contrast, echocardiography provides greater portability and flexibility for location of procedure performance, eliminates radiation exposure, provides important information about cardiac function, and safely allows biopsy of any area of the right ventricle, including the free wall and apex. We performed over 4,700 individual biopsies for evaluation of rejection in 58 patients who underwent orthotopic cardiac transplantation. Fluoroscopy was not required for any of the echocardiography-guided biopsies, and only two complications occurred in 4,700 biopsies. We propose, therefore, that echocardiography is a useful alternative or adjunct to fluoroscopy for guiding endocardial biopsy and is a technique that can be learned easily by anyone now performing biopsies.

Antilymphocyte Serum↗
PubMed1988

Seven years' experience with the Pierce-Donachy ventricular assist device.

Of currently available methods for mechanical circulatory support, the Pierce-Donachy external pneumatic ventricular assist device has proved to be one of the most versatile and effective. Since 1981, 48 patients, aged 15 to 71 years (mean 43.0), with profound cardiogenic shock refractory to conventional therapy with drugs and intra-aortic balloon support, were supported with the Pierce-Donachy ventricular assist device. There were four patient groups. The largest group consisted of 30 patients with cardiogenic shock after cardiac operations. Nine required left ventricular support, six needed right ventricular support plus an intraaortic balloon pump, and 15 had biventricular support. Duration of support ranged from 3 hours to 22 days (mean 3.6 days). Eight of the first 11 patients died in the operating room of bleeding and/or biventricular failure. However, 16 patients, (53%) had improved cardiac function, 15 (50%) were weaned, and 11 (36%) were discharged. Of the last 19 patients, 47% survived. Frequent factors in nonsurvivors were myocardial infarction (75%) and renal failure (90%). Common complications in all patients were bleeding (52%) and infection (27%). The second group consisted of 11 patients with end-stage cardiomyopathy or acute myocardial infarction in whom the Pierce-Donachy ventricular assist device was used as a bridge to transplantation (left ventricular support, four patients; biventricular support, seven patients). Renal failure, infection, or coagulopathy that precluded transplantation developed in five patients. Five patients were supported for 8 hours to 75 days (mean 20.7 days) before undergoing successful transplantation, with one late death (six months) from rejection owing to noncompliance. One has subsequently undergone successful transplantation after 84 days of support. The third group consisted of four patients, aged 40 to 56 years (means 47.2), who had refractory cardiogenic shock after cardiac transplantation caused by pulmonary hypertension (two patients), hyperacute rejection (one patient), or graft failure (one patient). Despite biventricular support in all four (biventricular assist devices, two patients; right ventricular assist device plus intraaortic balloon pump, two patients), all died of infection and/or renal failure after 12 hours to 6 days (mean 3.4 days) of support. The final group consisted of three patients, aged 36 to 51 years (mean 45), with cardiogenic shock caused by acute myocardial infarction. One patient was supported with biventricular assist devices (3.5 days) and two patients were supported with a left ventricular assist device (8.5 and 15 days).(ABSTRACT TRUNCATED AT 400 WORDS)

Adolescent↗
PubMed1988

Effect of perioperative myocardial infarction on survival of postcardiotomy patients supported with ventricular-assist devices.

Ventricular-assist devices (VAD) have increased survival in patients with postcardiotomy shock, but the predictors of success need to be elucidated. We evaluated 45 patients treated with centrifugal (n = 18) or pulsatile (n = 27) VAD for postcardiotomy cardiogenic shock to determine the effect of perioperative myocardial infarction (PMI) on survival. The patients ranged in age from 15 to 72 years (mean age, 55.1 years). VAD support was left ventricular in 29, right ventricular in seven, and biventricular in nine, and the flow-rate range was 1.6-5.2 l/min (mean rate, 3.97 l/min) for 0.2-22 days (mean time, 4.1 days). PMI was determined by analysis of postoperative electrocardiogram (EKG), enzyme levels, or at necropsy. PMI was considered "possible" if there were either EKG or enzyme level changes, and "definite" if there were EKG and enzyme level changes or necropsy evidence. Of the 45 patients, 19 were successfully weaned from ventricular assistance; 12 were discharged (Group 1), and seven died (Group 2); the remaining 26 patients could not be weaned from VAD support (Group 3). In Group 1, one patient had a definite PMI, and three had a possible PMI. Among the 33 nonsurvivors (Groups 2 and 3), 24 patients had PMI by necropsy examination. Definite PMI was much more common in nonsurvivors (72.7%) than in survivors (8.3%) (p less than 0.05). However, Group 2 nonsurvivors were weaned despite PMI in 100% of cases. These data suggest that, although PMI is a strong negative determinant of survival in postcardiotomy patients, it cannot be considered a contraindication because it does not preclude myocardial recovery.

Adolescent↗
PubMed1987

Tricuspid regurgitation by Doppler echocardiography after orthotopic cardiac transplantation.

The incidence and severity of Doppler-detected tricuspid regurgitation (TR) and associated clinical variables was studied in 20 patients who underwent cardiac transplantation. Eighteen of the 20 patients had Doppler detectable TR after cardiac transplantation, 14 had moderate to severe TR and 4 mild TR. Echocardiographic evidence of right ventricular volume overload was present in 13 of 14 patients with moderate to severe TR and in none of the other 6 patients. Patient age, primary disease process, cold ischemic time of the transplanted heart, and the frequency or severity of organ rejection did not correlate with the development of TR. Two patients with significant TR had a torn or partially torn tricuspid chordae, indicating an organic etiology, and the remaining patients had functional TR. All 8 patients with a pulmonary artery systolic pressure of 55 mm Hg or more before transplantation had significant functional TR after transplantation (p less than or equal to 0.05). Pulmonary vascular resistance before transplantation was not predictive; however, after transplantation pulmonary vascular resistance was significantly greater in patients with moderate to severe TR (101.6 +/- 41.3 vs 50.2 +/- 16.6 dynes s cm-5, p less than or equal to 0.01).

Adolescent↗
PubMed1985

Heart graft arteriosclerosis. An ominous finding on endomyocardial biopsy.

Heart graft arteriosclerosis remains a severe and irreversible complication of allogeneic heart transplantation despite prophylactic therapy. Immunologically mediated endothelial damage has been proposed as a stimulus for the development of graft arteriosclerosis. The vascular lesions may accumulate large amounts of lipid resembling atheromas, or may be purely proliferative, as illustrated in the case of a 42-year-old heart transplant patient who developed slowly progressive graft dysfunction at eight months posttransplantation. Endomyocardial biopsy ten months posttransplantation revealed proliferative arteriolar occlusion, while changes on the coronary angiogram were minimal. Repeat biopsy at eleven months showed ischemic myocardial necrosis. The patient expired shortly thereafter. On postmortem examination, proliferative graft arteriosclerosis affecting both intramural and epicardial vessels was present, along with massive biventricular infarction. Tissue immunofluorescence studies demonstrated extensive vascular deposition of immunoglobulin and complement. We propose that (1) the presence of proliferative arteriolar occlusion on endomyocardial biopsy is predictive of poor heart graft survival; (2) proliferative graft arteriosclerosis may appear as advanced small vessel disease before extensive large vessel involvement is detected by coronary angiogram; and (3) immunofluorescence results support an immune-mediated mechanism of vascular injury in proliferative heart graft arteriosclerosis.

Adult↗
PubMed1985

Improved myocardial preservation by control of the oxidation-reduction potential.

Simple cold storage remains the current method of preservation of human heart allografts between removal and transplantation, but this technique is not adequate for prolonged periods of preservation. An alternative to cold storage is machine perfusion of the isolated organ. Although this technique has yielded promising results in kidney preservation, there is limited experience with the heart. One factor limiting the effectiveness of perfusion preservation is the toxicity of oxygen free radicals generated during the perfusion. The generation and reduction of these radicals results in an electron transfer, producing an electrochemical potential known as the redox potential. This study examines the role of machine perfusion in heart preservation with and without the use of a new electrochemical cell that is able to control the redox potential during the perfusion. Hearts were preserved for twenty-four hours by either simple cold storage (Group I), or by machine perfusion with redox monitoring (Group II), or redox control (Group III). Control of the oxidation-reduction potential of the perfusate during machine perfusion of isolated hearts resulted in significantly improved systolic and diastolic function after perfusion compared to hearts that underwent machine perfusion without redox control or simple cold storage.

Animals↗
PubMed1977

Clinical and serologic effects of live attenuated serum inhibitor-resistant influenza B vaccine in seronegative adults.

The clinical effects, nasal and serum antibody responses, and virus excretion of a live attenuated serum inhibitor-resistant influenza B virus vaccine, R75, was evaluated in 43 seronegative healthy adults by a random double-blind study. Symptom responses were minimal and were not significantly different between vaccine and placebo groups. No fevers, abnormalities in physical examination or laboratory testing developed during 4 weeks of observation. Among vaccinees, 10 (48%) developed serum hemagglutination-inhibition (HI) antibodies, 16 (76%) developed serum neutralization (N) antibodies and 4 (19%) developed nasal N antibodies. The GMT responses from study day 0 to day 28 were 4.0 to 10.4 for serum HI, 1.8 to 9.8 for serum N, and 1.0 to 1.4 for nasal N. There were no significant titer changes in the placebo group. No virus excretion was detected. Although there are some questions concerning the relationship of antibody levels to protection, the low antibody responses in this study are an indication that R75 is not sufficiently immunogenic.

Adult↗
PubMed1975

Clinical and serologic effects of Alice strain live attenuated influenza A (H3N2) virus vaccine in an adult population.

Alice strain live attenuated influenza A (H3N2) virus was evaluated in prison volunteers. By random double blind allocation, 94 volunteers received Alice strain vaccine (AS) intranasally and 97 received placebo. The vaccine was well tolerated, and there was no serious morbidity. The number, type, duration, and severity of symptoms was not significantly different between the vaccine and placebo groups. Seventy-five per cent of vaccines with initial HAI titers less than or equal to 1:8 had 4 fold or greater titer responses on day 30. Placebo recipients experienced no titer changes. The GMT among vaccinees increased from 23.5 prior to vaccination 59.7 30 days later. Surveillance activities failed to document influenza A (H3N2) infection in the volunteer population during a 6 month follow-up period. Additional studies on the protective effects of the vaccine are required before efficacy can be determined.

Adult↗
PubMed1975

Alice strain live attenuated influenza (H3N2) vaccin in an elderly population.

The clinical and antibody responses to Alice strain (AS) live attenuated influenza A (H3N2) vaccine and killed parenteral (KP) bivalent influenza vaccine were compared in a randomly allocated group of 150 elderly volunteers. AS recipients experienced more symptoms but these were mild and short in duration. Rhinitis occurred in 45% and pain at injection site in 25% of the AS and KP groups, respectively. Influenza A (H3N2) serum hemmaglutination inhibition titer responses were significantly higher in KP vaccinees; 95% of KP AND 60% OF AS recipients with initial titers smaller than or equal to 1:16 had fourfold or greater titer rises. KP induced significantly higher nasal neutralization titers but the proportion with fourfold or greater responses was not significantly different. Previous studies have shown poor correlations between antibody levels induced by live influenza vaccines and protection. Natural and/or challenge studies are needed before efficacy of influenza vaccines can be established.

Aged↗
PubMed1974

Diphtheria carriers and the effect of erythromycin therapy.

One hundred and fourteen Corynebacterium diphtheriae, toxigenic, gravis type, pharyngeal carriers were identified during a diphtheria epidemic in Elgin, Texas. All carriers were treated with erythromycin estolate, 1 g/day in divided doses for 6 days. Serial pharyngeal cultures were obtained in order to monitor the bacteriological response. Seventy-two carriers had positive cultures immediately prior to the start of therapy, and only these individuals were considered in the analysis of the effects of erythromycin. Forty-eight hours after institution of therapy, 96% of the carriers had become culture negative; all were negative by the 4th day of therapy, and all remained culture negative while taking the drug. Two days after cessation of therapy, all but one (99%) were culture negative. However, upon reculture 2 weeks later, 15 (21%) had relapsed to the carrier state. There were no significant differences in the serum diphtheria antitoxin levels, immunization status, age, sex, or socioeconomic status of those who relapsed and those who remained culture negative. This study demonstrates that erythromycin is effective in converting carriers to culture-negative status, but when given for only 6 days it is associated with large numbers of relapses. Because previous studies have not included follow-up cultures 2 weeks after therapy, it is suggested that all C. diphtheriae carriers be treated with either erythromycin or penicillin and that all be recultured at a minimum of 2 weeks after completion of therapy to assure eradication of the diphtheria organisms.

Adolescent↗